Core Laboratories Inc.CLBEarnings & Financial Report
Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.
CLB Q1 FY2026 Key Financial Metrics
Revenue
$121.8M
Gross Profit
N/A
Operating Profit
$1.9M
Net Profit
$5.1M
Gross Margin
N/A
Operating Margin
1.5%
Net Margin
4.2%
YoY Growth
-1.4%
EPS
$0.11
Core Laboratories Inc. Q1 FY2026 Financial Summary
Core Laboratories Inc. reported revenue of $121.8M (down 1.4% YoY) for Q1 FY2026, with a net profit of $5.1M (4.2% margin).
Key Financial Metrics
| Total Revenue | $121.8M |
|---|---|
| Net Profit | $5.1M |
| Gross Margin | N/A |
| Operating Margin | 1.5% |
| Report Period | Q1 FY2026 |
Core Laboratories Inc. Annual Revenue by Year
Core Laboratories Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $526.5M).
Core Laboratories Inc. Quarterly Revenue & Net Profit History
Core Laboratories Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $121.8M | -1.4% | $5.1M | 4.2% |
| Q4 FY2025 | $138.3M | +7.0% | $4.9M | 3.6% |
| Q3 FY2025 | $134.5M | +0.1% | $14.2M | 10.6% |
| Q2 FY2025 | $130.2M | -0.3% | $10.6M | 8.2% |
| Q1 FY2025 | $123.6M | -4.7% | $-154.0K | -0.1% |
| Q4 FY2024 | $129.2M | — | $7.4M | 5.7% |
| Q3 FY2024 | $134.4M | +7.2% | $11.7M | 8.7% |
| Q2 FY2024 | $130.6M | +2.1% | $9.0M | 6.9% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $130.6M | $134.4M | $129.2M | $123.6M | $130.2M | $134.5M | $138.3M | $121.8M |
| YoY Growth | 2.1% | 7.2% | N/A | -4.7% | -0.3% | 0.1% | 7.0% | -1.4% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $597.8M | $600.5M | $585.1M | $591.5M | $602.1M | $591.4M | $584.0M | $587.7M |
| Liabilities | $357.5M | $349.7M | $338.6M | $338.1M | $340.8M | $320.0M | $318.0M | $312.6M |
| Equity | $240.3M | $250.7M | $246.6M | $253.4M | $261.3M | $271.3M | $266.0M | $275.1M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $17.1M | $13.1M | $20.6M | $6.7M | $13.9M | $8.5M | $7.9M | $4.0M |